2 active not recruiting, 1 completed. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Active not recruiting 2, Completed 1 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Movember Foundation: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to Prostatectomy 177Lu-PSMA-617 - Prostatic Neoplasms | Phase 1 / Phase 2 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 20 | 2020-08-06 | 2024-11-08 |
| In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to Chemotherapy 177Lu-PSMA-617, Docetaxel - Metastatic Hormone Naive Prostate Cancer | Phase 2 | Active not recruiting | Peter MacCallum Cancer Centre, Australia | 130 | 2020-04-21 | 2025-07-11 |
| A Trial of 177Lu-PSMA617 Theranostic Versus Cabazitaxel in Progressive Metastatic Castration Resistant Prostate Cancer 177Lu-PSMA617, Cabazitaxel - Cancer of the Prostate, Metastatic Cancer | Phase 2 | Completed | Australian and New Zealand Urogenital and Prostate Cancer Trials Group | 201 | 2018-01-29 | 2022-06-13 |
Prostatic Neoplasms (2) · Neoplasm Metastasis (1)
Pluvicto (3) · Docetaxel (1) · cabazitaxel (1)
Australia (3)
Arun Azad, MBBS PhD FRACP (1) · Declan Murphy (1) · John Violet (1) · Michael Hofman, A/Prof (1) · Michael Hofman, MBBS(Hons),FRACP,FAANMS,FICIS (1) · Michael S Hofman (1)
PMID 31595044, PMID 33581798, PMID 34373282, PMID 36261050, PMID 36350899, PMID 37891072, PMID 38043558, PMID 39293461, PMID 40425844